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Summary The sulfhydryl status of normal and tumour cells is critically important in determining their
susceptibility to various cytostatic agents. As a sulfhydryl compound, mesna (sodium 2-mercaptoethane-
sulfonate) which is used in large doses to prevent haemorrhagic cystitis associated with certain
chemotherapeutic regimens might derange cellular thiol homeostasis. In order to investigate the effects of
mesna on the concentrations of thiols in plasma, cysteine, glutathione and their disulfides were measured by
HPLC following the oral and intravenous administration of mesna to healthy volunteers. After 7.3 mmol
mesna i.v. free cysteine rose from 8.2 (95% CI 7.0-9.4)nmol ml' to 53.6 (47.4-59.8) nmol ml-' at 5 min,
most likely due to reduction of circulating cystine by the sulfhydryl drug. This initial rise was followed by a
marked decrease of total cyst(e)ine in plasma from 276 (215-337) nmol ml-' to a nadir of 102
(89-115) nmol ml-' between 30-120 min after infusion, most likely due to an increased uptake of cysteine
into cells and an increased urinary excretion of cyst(e)ine. Qualitatively similar changes were seen after oral
mesna. The present data indicate that mesna depletes circulating cyst(e)ine and may thereby markedly alter the
sulfbydryl status of cells in vivo although the drug itself is not taken up by most cells.
The sulfhydryl status of tumour cells is critically important in
determining their susceptibility to various cytostatic agents
(McGown & Fox, 1986). Similarly, the sulfhydryl status of
normal cells is an important determinant of their defense
against the toxic effects of the same cytostatic drugs
(Chasseaud, 1979). Mesna (sodium 2-mercaptoethane-
sulfonate) is increasingly used to prevent haemorrhagic cys-
titis associated with chemotherapeutic regimens containing
high doses of ifosfamide and cyclophosphamide (Dechant et
al., 1991). Although mesna is very polar and does not pas-
sively enter cells to a significant extent (Ormstad et al., 1983),
the sulfhydryl drug could still markedly affect cellular thiol
homeostasis. High concentrations of the sulfhydryl could
reduce circulating cystine, thereby making more cysteine
available to cells since cysteine is more readily taken up by
many cell types than cystine (Issels et al., 1988). In addition,
cysteine-mesna mixed disulfides have been identified in urine
(Jones et al., 1985; Duran et al., 1981). Mesna might thus
result in a substantial loss of cyst(e)ine. Since the effects of
intravenous and oral mesna on circulating physiological
thiols are not known and the mesna-induced loss of
cyst(e)ine has not been quantitated, the concentrations of
cysteine, glutathione and their disulfides in plasma and urine
were measured following the oral and intravenous administ-
ration of mesna to healthy volunteers.
Subjects and methods
The effects of mesna (sodium-2-mercaptoethane-sulfonate) on
plasma cyst(e)ine and glutathione after intravenous and oral
administration were studied in eight healthy volunteers, two
females and six men, 24 to 39 years of age, all within 10% of
ideal body weight. Informed consent was obtained from each
of the participants. The study was approved by the ethics
committee of the local medical school. After an overnight
fast an indwelling catheter was placed into an antecubital
vein of both arms in order to obtain blood repeatedly with-
out tourniquet. Two blood samples were obtained 10 min
apart before the administration of mesna in order to deter-
mine the basal concentrations of glutathione and
cyst(e)ine.
Intravenous mesna was infused over 2 min at a dose of
1.2 g (7.3 mmol; ASTA MEDICA, 400 mgml-') and blood
samples were obtained 0, 5, 10, 15, 30, 60, 120, 240 min after
termination of the infusion. Urine was collected before and
during the 4 h after administration of mesna. In two patients
peripheral blood mononuclear cells were isolated using
Ficoll-Paque at baseline and 30 and 120 min following the
infusion of mesna and were processed as previously described
for the determination of intracellular cysteine (DeQuay et al.,
1992).
Since much lower plasma concentrations of free mesna are
seen after oral administration (James et al., 1987) the effect
of oral mesna on the thiol status was also investigated.
Mesna was administered at a dose of 1.2 g (ASTA
MEDICA, four tablets of 300mg) together with 200 ml of
water and blood was collected after 0.5, 1, 1.5, 2, 2.5, 3, 4, 6
and 8 h. Urine was collected before ingestion of mesna and
at intervals thereafter for 8 h. Food and liquids were allowed
2 h after the administration of mesna.
Analytical methods
Five ml of blood were collected into heparinised tubes con-
taining L-serine-Na-borate (final concentration 2 mmol I') in
order to prevent the degradation of glutathione by gamma-
glutamyltransferase and were immediately centrifuged.
Within 2 min of collection plasma was derivatised with
monobromobimane (10 l of a solution of 25mmol 1' in
acetoninitrile; Thiolite reagent, Calbiochem, La Jolla, USA).
D-penicillamine served as internal standard. Calibration
curves were established daily by adding known amounts of
mesna, cysteine and glutathione to plasma samples (Stofer et
al., 1993).
Total mesna, cyst(e)ine and glutathione, i.e. free thiols,
thiol disulfides and small molecular and protein mixed
disulfides, were measured after reduction of disulfides with
dithiothreitol (Aebi et al., 1991). Total mesna and cyst(e)ine
in urine were measured following the same protocol as for
disulfides in plasma. Chromatography and quantification of
sulfhydryls were performed as previously described (Stofer et
al., 1993). Taking a blood sample five times through the
procedure the coefficients of variation for total mesna,
cyst(e)ine and GSH were 9.8, 1.6 and 3.0%, respectively. The
coefficients of variation for the corresponding free sulfhydrils
were <5%. The recovery of mesna, cystine and glutathione
disulfide added to plasma was 102 ± 10%, 105 ± 8% and
85 ± 9% (mean ± s.d., n = 5), respectively. The peak to noise
ratio for concentrations of cysteine and GSH of 5 j.mol I'
exceeds five.
Data analysis
The results are given as mean and 95% confidence inter-
vals.
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Results
After intravenous administration the plasma concentration of
mesna decreased from a peak of 511 (95% CI
404-617)nmolml-' at 5min with a half life of 19
(17-21)min. After oral administration peak concentrations
of 33 (26-40)nmolml-' were reached between 1.5 and 4h
after ingestion. Peak concentrations of total mesna, i.e. free
mesna and its disulfides, averaged 820 and 139nmolmlP'
following intravenous and oral administration, respectively
(Stofer et al., 1993).
As shown in Figure 1 intravenous mesna resulted in a
marked increase in circulating free cysteine from 8.2 (95% CI
7.0-9.4) nmol ml-' to 52.5 (44.1-61.0) nmol ml-' 5 min
after the end of the infusion, suggesting that mesna reduces
circulating cystine. In contrast to the early transient increase
in free cysteine total cyst(e)ine decreased from its basal con-
centration of 276 (215-337) nmol ml-' to a nadir of 102
(89-115) nmol ml-' between 30-120 min after infusion. The
concentrations gradually returned to 198 (165-230) nmol ml-'
at 4 h. Following oral administration of mesna a small in-
crease in free cysteine was again observed (Figure 2). Total
cyst(e)ine decreased from 241 (216-267)nmolml-' to a
nadir of 120 (97-142) nmol ml-' and had not returned to the
basal level by 8 h. There was a significant (P<0.001) correla-
tion between the increment in free cysteine and the peak
concentrations of free (r2 = 0.852) and total (r2 = 0.818)
mesna (Figure 3). The decrease in circulating cyst(e)ine
showed a significant (P<0.001) correlation (r2 = 0.579) with
the area under the plasma concentration time curve of free
mesna (Figure 3).
In contrast to cystine, cysteine is readily taken up by cells.
In order to see whether the mesna-induced increase in cir-
culating free cysteine resulted in an increased intracellular
concentration of cysteine peripheral blood mononuclear cells
were isolated and their cysteine content was measured. As
shown in Figure 4 there was a marked increase in intracel-
lular cysteine 30 min after infusing mesna in the two subjects
studied. Intracellular cysteine had returned to baseline by 2 h.
The decrease in circulating cyst(e)ine was associated with a
marked increase in the urinary excretion of the amino acid
from 40 (33-47) nmol cysteine jimol-' creatinine to 105
(90- 120) nmol pimol-I creatinine during the 4 h following the
intravenous administration of mesna. Assuming a constant
excretion of creatinine throughout the day the mesna-induced
increment in the urinary excretion of cysteine averaged
0.26 mmol in 4 h. Following oral administration of mesna
the urinary excretion ofcyst(e)ine increased to 153 (116-190)
between 2-4 h, 120 (96-143) between 4-6 h, and 79
(63-95)nmolcyst(e)inepmol-' creatinine between 6-8h
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Figure 1 Plasma concentrations of free cysteine (squares) and
total cyst(e)ine (triangles) following intravenous infusion of 1.2 g
of mesna (mean + 95% CI, n = 8).
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Figure 2 Plasma concentrations of free cysteine (squares) and
total cyst(e)ine (triangles) following oral administration of 1.2 g
of mesna (mean + 95% CI, n = 8).
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Figure 3 Correlation between the peak concentration of free mesna and the increment in cysteine (r2 = 0.852) and between the
decrease in circulating total cyst(e)ine and the area under the plasma concentration time curve of free mesna (r2 = 0.579) following
oral (open circles) and intravenous (closed circles) administration of mesna. Stippled lines = 95% confidence interval.
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Figure 4 Concentration of cysteine in peripheral blood
mononuclear cells isolated from two subjects before and 30 and
120min after the intravenous administration of mesna.
after oral dosing. The mesna-induced urinary loss of
cyst(e)ine during the 8 h following the oral administration
amounted to 0.52 (0.42-0.63) mmol.
Following intravenous mesna there was a small rise in
circulating free glutathione (Figure 5). No change in free and
total glutathione was seen after oral mesna. No glutathione
was found in urine.
Discussion
Mesna had two striking effects on circulating cyst(e)ine:
First, it markedly increased circulating free cysteine, and
secondly, it resulted in profound depletion ofcirculating total
cyst(e)ine. The effect on free cysteine was much more evident
following intravenous administration when markedly higher
concentrations of free mesna are achieved than after oral
administration. A similar increase in free cysteine has
previously been seen after the intravenous administration of
large doses of glutathione (Aebi et al., 1991), suggesting that
it most likely results from the reduction of cystine by high
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circulating concentrations of thiols. In contrast to cystine,
cysteine is readily taken up by cells (Issels et al., 1988). Thus,
rising the concentration of free cysteine in the extracellular
space would be expected to increase the intracellular concen-
tration ofcysteine. Indeed, in the two subjects where intracel-
lular cysteine was measured there was a transient marked
increase in intracellular cysteine (Figure 4).
A shift of cysteine from the extracellular to the intracel-
lular compartment can in part explain the second effect of
mesna on circulating cyst(e)ine, namely the marked depletion
of total cyst(e)ine which followed the initial rise in free
cysteine. In addition, mesna resulted in a marked increase in
the urinary excretion of cyst(e)ine. Mesna is in part excreted
in the form ofmesna-cysteine disulfide and may also circulate
as a mixed disulfide (Jones et al., 1985; Duran et al., 1981).
This fraction appears to be larger after oral administration
such that more cyst(e)ine is lost via the kidneys following
oral administration. Free cysteine in urine may contribute to
the uroprotective effects of mesna.
Mesna had minimal short-term effects on circulating
glutathione. In contrast to cystine, glutathione disulfide and
mixed disulfides account for less than 50% of total cir-
culating glutathione. Thus, in the presence of even high
concentrations of mesna much less free glutathione than
cysteine will be generated.
The quantitative importance and the metabolic conse-
quences of the suggested translocation ofcysteine are difficult
to assess. Assuming a volume of distribution for total
cyst(e)ine corresponding to the extracellular space the
observed depletion of cyst(e)ine 1 h following intravenous
mesna corresponds to an estimated disappearance of
1-2mmol of cyst(e)ine. Since the increment in the urinary
excretion of cyst(e)ine during the first 4 h amounted to only
about one fourth of this amount substantial quantities of
cysteine must have been translocated into cells.
Since the availability of cysteine is rate-limiting for the
synthesis of glutathione in vivo (Aebi et al., 1992), transloca-
tion of extracellular cysteine into the intracellular compart-
ment might result in an increased synthesis of glutathione
which plays an important role in the detoxification of reac-
tive metabolites of cytostatic agents and other compounds.
On the other hand, the turnover of cysteine is very rapid
(Lauterburg et al., 1984), such that a substantial fraction of
the increased cellular content of cysteine may be utilised by
pathways other than glutathione synthesis. Such an increase
in the catabolism of cysteine might eventually decrease the
availability of cysteine and lead to depletion of glutathione.
Preliminary results of an ongoing study in patients who
receive mesna together with ifosfamide by continuous
infusion show a marked depletion of circulating cyst(e)ine,
glutathione and homocysteine, indicating that similar changes
in sulfhydryl homeostatis occur during chemotherapy.
The present data indicate that the reaction of the free
sulfhydril group of mesna with endogenous disulfides is prob-
ably mainly responsible for the mesna-induced disruption of
thiol homeostasis. Since oral mesna increases circulating free
cysteine to a lesser extent than intravenous mesna and leads
to a more marked increase in urinary cyst(e)ine which may
contribute to uroprotection, oral administration of mesna
may be preferable. In view of the fact that the efficacy of
mesna critically depends on the reduction by the kidneys of
mesna-mixed disulfides and dimesna a case could be made
for the therapeutic use of dimesna which exhibits comparable
uroprotective properties as mesna (Shaw & Weeks, 1987) but
is not likely to interfere with thiol homeostasis to the same
extent as mesna.
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Figure 5 Plasma concentrations of free glutathione following
intravenous infusion of 1.2 g of mesna (mean + 95% CI,
n = 8).
Supported by grant # 32-29943.90 from the Swiss National Found-
ation for Scientific Research and ASTA Medica.
0 J
3 3 4
I Ix|DEPLETION OF CYST(E)INE BY MESNA 593
References
AEBI, S., ASSERETO, R. & LAUTERBURG, B.H. (1991). High dose
intravenous glutathione in man. Pharmacokinetics and effects on
cyst(e)ine in plasma and urine. Europ. J. Clin. Invest., 21,
103-110.
AEBI, S. & LAUTERBURG, B.H. (1992). Divergent effects of intra-
venous GSH and cysteine on renal and hepatic GSH. Am. J.
Physiol., 263, R348-R352.
CHASSEAUD, L.D. (1979). The role of glutathione and glutathione
S-transferases in the metabolism of chemical carcinogens and
other electrophilic agents. Adv. Cancer Res., 29, 175-274.
DECHANT, K.L., BROGDEN, R.N., PILKINGTON, T. & FAULDS, D.
(1991). Ifosfamide/mesna. A review of its antineoplastic activity,
pharmacokinetic properties and therapeutic efficacy in cancer.
Drugs, 42, 428-467.
DEQUAY, B., MALINVERNI, R. & LAUTERBURG, B.H. (1992).
Glutathione depletion in HIV-infected patients: role of cysteine
deficiency and effect of oral N-acetylcysteine. AIDS, 6,
815-819.
DURAN, M., AARSEN, G., FOKKENS, R.H., NIBBERING, N.M., CATS,
B.P., DEBREE, P.K. & WADMAN, S.K. (1981). 2-Mercapto-
ethanestulfonate-cysteine disulfide excretion following the
administration of 2-mercaptoethanesulfonate - a pitfall in the
diagnosis of sulfite oxidase deficiency. Clin. Chim. Acta, 111,
47-53.
ISSELS, R.D., NAGELE, A., EXKERT, K.G. & WILMANNS, W. (1988).
Promotion of cystine uptake and its utilization for glutathione
biosynthesis induced by cysteamine and N-acetylcysteine.
Biochem. Pharmacol., 37, 881-888.
JAMES, C.A., KANT, T.G.K. & ROGERS, H.J. (1987). Phar-
macokinetics of intravenous and oral sodium 2-mercapto ethane
sulphonate (mesna) in normal subjects. Br. J. Clin. Pharmacol.,
23, 561-568.
JONES, M.S., MURRELL, R.D. & SHAW, I.C. (1985). Excretion of
sodium 2-mercaptoethanesulphonate (MESNA) in the urine of
volunteers after oral dosing. Eur. J. Cancer Clin. Oncol., 21,
553-555.
LAUTERBURG, B.H., DAVIES, S., & MITCHELL, J.R. (1984). Ethanol
suppresses hepatic glutathione synthesis in rats in vivo. J. Phar-
macol. Exp. Ther., 230, 7-11.
MCGOWN, A.T. & FOX, B.W. (1986). A proposed mechanism of
resistance to cyclophosphamide and phosphoramide mustard in a
Yoshida cell line in vitro. Cancer Chemother. Pharmacol., 17,
223-236.
ORMSTAD, K., ORRENIUS, S., LASTBOM, T., URHARA, N., POHL, J.,
STEKAR, J. & BROCK, N. (1983). Pharmacokinetics and
metabolism of sodium 2-mercaptoethanesulfonate in the rat.
Cancer Res., 43, 333-338.
SHAW, I.C. & WEEKS, M.S. (1987). Excretion of disodium bis-2-
mercaptoethanesulphonate (dimesna) in the urine of volunteers
after oral dosing. Eur. J. Cancer Clin. Oncol., 23, 933-935.
STOFER-VOGEL, B., CERNY, T., BORNER, M. & LAUTERBURG, B.H.
(1993). Oral bioavailability of mesna tablets. Cancer Chemother.
Pharmacol., 32, 78-81.